SITE013-0196

completed

Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE013 (USA) (Dr. Clarke) · consented 2022-10-23

Adverse events

Serious AEs

Open data queries

Luna dropout signal

–

Adverse events

moderate assessed 2026-08-18

Grade 2 Anaemia — outcome: UNKNOWN; onset 2022-12-12 (study day 40); relationship: N

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-18 (study day 108); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-02-21 (study day 111); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-03-15 (study day 133); relationship: not assessed

severe serious assessed 2026-08-18

Grade 4 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-19 (study day 137); relationship: not assessed; serious criteria: life-threatening

moderate assessed 2026-08-18

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-04-07 (study day 156); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-05-24 (study day 203); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.